Latest News
Pharmacist's Application to Practice: Taletrectinib
Benjamin Pastore, PharmD, PGY2 Adult Oncology Pharmacy Resident, and Jasmine Patel, PharmD, BCOP, Clinical Pharmacy Specialist - Thoracic Oncology, discuss the potential role of taletrectinib in the treatment of metastatic non-small cell lung cancer.
Pharmacist's Application to Practice: Zongertinib
Reyam Katchi, PharmD, PGY2 Hematology/Oncology Pharmacy Resident, and Kiera Roubal, PharmD, Oncology Clinical Pharmacist, break down the potential role for zongertinib in the treatment of non-squamous NSCLC with HER2 TKD activating mutations.
Late-Breaking HOPA News: NeoADAURA: Advancing Neoadjuvant Osimertinib for Resectable EGFR-Mutated NSCLC
Wai Tak Vince Sung, PharmD, MBA, BCOP, BCSCP, breaks down the results from the NeoADAURA trial and what its findings may mean for neoadjuvant osimertinib's role in the treatment of resectable EGFR-mutated NSCLC.
Proposed Student Loan Limits for Nursing and Other Professions Will Contribute to Healthcare Worker Shortages
HOPA is concerned about the Department of Education's proposed language and student loan limits for professions crucial to oncology care, especially nursing. Implementation will contribute to the shortage of healthcare workers in this country.
As 2026 Forges Ahead, A Look Back at HOPA in 2025
2025 certainly brought challenges both new and familiar to HOPA, our members, our patients, and those dear to them. But it's also brought hope. It's brought progress. And it's brought an inspiring sense of purpose, passion, and community.
Explore more from HOPA
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
The data from this trial confirm that FTD–TPI plus bevacizumab is an effective treatment option for patients with refractory metastatic colorectal cancer, irrespective of mutational status, which side the tumor is on, and whether patients have previously
